Skip to content
lifestyle.ukuncut.org.uk
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary Endpoint
October 30, 2026
Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights
October 26, 2026
Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
October 22, 2026
Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026
October 19, 2026
Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026
September 10, 2026
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
September 2, 2026
Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights
August 12, 2026
Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026
August 5, 2026
Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights
May 12, 2026
Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference
May 7, 2026
1
2
Next Page
→